Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.57 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239233 | 0.88 | KCNH2 (0.55) | KCNH2MAOBGAAMAPTACHE | |
| SCHEMBL2478557 | 0.79 | KCNH2 (0.60) | KCNH2ALDH1A1GAALMNASMN1; SMN2 | |
| SCHEMBL1226094 | 0.79 | MEN1 (0.49) | ALDH1A1GAALMNASMN1; SMN2CRHBP | |
| SCHEMBL10828222 | 0.76 | KCNH2 (0.56) | KCNH2ALDH1A1GAAMAPTBCHE | |
| SCHEMBL28612143 | 0.75 | KCNH2 (0.58) | KCNH2GAAMAPTACHECRHBP | |
| SCHEMBL1962562 | 0.74 | KCNH2 (0.68) | KCNH2ABCG2GAAMAPT | |
| SCHEMBL5954167 | 0.74 | PTGES (0.43) | KCNH2ALDH1A1GAALMNAMAPT | |
| SCHEMBL26239791 | 0.74 | KCNH2 (0.46) | KCNH2ALDH1A1GAAMAPTACHE | |
| SCHEMBL9385068 | 0.74 | KCNH2 (0.74) | KCNH2MAOBALDH1A1LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3570004 | 0.73 | KCNH2 (0.67) | KCNH2ABCG2GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | ACAD PHARMACEUTICALS INC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | ACADEMIC PHARMACEUTICALS INC (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11731938-B2 | Ultra short acting anti-arrhythmic agents | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885ABCG2 314/4885MAOB 2887/4885 |
| US-20240025846-A1 | ULTRA SHORT ACTING ANTI-ARRHYTHMIC AGENTS | CACNA1G, SCN5A, CACNA1F | KCNH2 51/4885ABCG2 314/4885MAOB 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.